IMMUNO-ONCOLOGY SERVICES

Immuno-oncology is a most exciting new development in cancer research and has emerged as a compelling area of personalized medicine with its tremendous potential to harness our powerful immune system to target and destroy cancer cells with few side effects. Researchers are exploring the complex relationship between tumor and the immune system within the tumor microenvironment in order to discover new immuno-oncology targets and therapies. A deep understanding of these targets is the key to unlocking the next blockbuster immunotherapy, kickstarting our immunity to fight cancer. Our -immuno-oncology solutions span the entire drug discovery workflow, from drug screening, pre-clinical efficacy, to evaluation of human tumor samples from clinical trials. Our immune cell function assays, along with our immunoassays, are the perfect fit for these researches and developments, providing a broad range of highly reproducible, sensitive solutions for high-throughput screening, biomarker validation and efficacy studies. 

•  T cell activation and proliferation (MLR, anti-CD3/CD28; PHA/Con A, PMA/ionomycin, SEB, anti-PD1, anti-CTLA4) via high throughput Flow Cytometry, or BrdU assay
• Antigen-specific recall response assay
• Target expression profiling on cell subsets (resting and activated)
• Screening for the ability to reverse T cell exhaustion
• Suppression assay with regulatory T cells.
• Modulation of differentiation and cytokine profile
• Immune cell migration assay
• mixed lymphocyte reaction (PBMC/T cell/DC, one way or two-way)
• immune checkpoint blockade assay
• Cytokine secretion profile (ELISA, Luminex, ELISpot)
• T Cell Surface marker expression analysis (Flow cytometry)

• Target expression on NK cells
• Modulation of activation and killing
• Antibody-dependent cellular cytotoxicity (ADCC)

•  Target expression profiling on subsets (resting vs. activated)
• Screening for modulation of M1/M2/MDSC (e.g., differentiation)
• Screening for modulation of tumor-conditional response (phenotype and cytokine/chemokine production)
• Effects on antigen presentation
• Antibody-dependent cellular phagocytosis (ADCP)

•  Target expression profiling on B cell subsets (resting and activated)
• Modulation of antibody production
• Modulation of antigen-presenting cell function and cytokine release
• BCR signaling (BTK, CARD11/BCL10/MALT1 complex)

•  Degranulation and histamine release
• Cell migration and chemotaxis

• Target expression profiling on cell subsets
• Effects on antigen presentation/killing assays
• Modulation of checkpoint ligand expression
• Modulation of tumor derived immune modulating factors (e.g.eicosanoids, chemokines, cytokines)
• Direct cytotoxicity
• Phagocyte Degranulation

•  ADCC (antibody-dependent cell-mediated cytotoxicity assays)
• CDC (complement-dependent cytotoxicity assays)
• ADCP (antibody-dependent cellular phagocytosis)
• T cell killing – LDH assay
• NK mediated cell killing assay (FACS based)

• Biochemical and cell-based screening assays for novel immunotherapy. 
• IC50 determination for small or large molecules against immune targets for:  PD-1:PD-L1/2,   PD-L1:B7-1, CTLA4:B7-1,  CTLA4:B7-2, BTLA:HVEM, CD28:B7-1, CD40: CD40L, CD47:Sirpα, CD137:CD137L, OX40:OX40L, GITR:GITRL, TIGIT: CD155,  IDO/TDO, COX1/COX2